

REFERENCIAS. APROXIMACIÓN A LOS TRATAMIENTOS PSICOFARMACOLÓGICOS EN EL EMBARAZO.

- 1) Actualización del uso de fármacos durante el embarazo: categorías de riesgo
M. Gallego Úbeda, L. Delgado Téllez de Cepeda, M.a de los A. Campos
Fernández de Sevilla, A. de Lorenzo Pinto y F. Tutau Gómez
Servicio de Farmacia. Hospital Universitario del Henares. Coslada.
Madrid. Farm Hosp. 2014;38(4):364-378
- 2) Collaborative group on drug use in pregnancy. Medication during pregnancy: an intercontinental cooperative study. Int J Gynecol Obstet. 1992; 39: 185-96
- 3) Estudio multicéntrico sobre el uso de medicamentos durante el embarazo en España (III). Los fármacos utilizados durante el primer trimestre de la gestación. Med Clin (Barc). 1991; 96: 52-7.
- 4) J Clin Pharmacol Ther. 1997 Dec;35(12):572-6.
The PEGASUS project--a prospective cohort study for the investigation of drug use in pregnancy. PEGASUS Study Group
- 5) Marín GH et al. Uso de fármacos durante el período de gestación en embarazadas de Buenos Aires, Argentina. Rev Salud Pública. 2010; 12: 722-31.
- 6) Análisis clínico epidemiológico de los recién nacidos con defectos congénitos registrados en el ECEMC distribuidos por etiología y por grupos étnicos. Boletín del ECEMC. Revista de disformia y Epidemiología. Serie V no9 2010. ISSN: 0210-3893).
- 7) J Clin Psychiatry. 2002;63 Suppl 4:42-55.
The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics.
Ernst CL, Goldberg JF.
- 8) FDA/CDER SBIA CHRONICLES. Drugs in Pregnancy and Lactation: Improved Benefit-Risk Information. Disponible en. <http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM431132.pdf>.
- 9) Gee RE, Wood SF, Schubert KG. Women's health, pregnancy, and the US Food and Drug Administration. Obstet Gynecol. 2014;123(1):161-5
- 10) Ni A, Mao Q. ATP-Binding Cassette Efflux Transporters in Human Placenta. Curr Pharm Biotechnol. 2011; 12(4): 674-685.

REFERENCIAS. APROXIMACIÓN A LOS TRATAMIENTOS PSICOFARMACOLÓGICOS EN EL EMBARAZO.

11) Br J Clin Pharmacol. 2008 Apr;65(4):600-6. Epub 2007 Oct 22.
Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands.
Bakker MK1, Kölling P, van den Berg PB, de Walle HE, de Jong van den Berg LT.

12 Am J Psychiatry. 2013 Mar;170(3):299-304. doi: 10.1176/appi.ajp.2012.11081251.
SSRI use during pregnancy and risk of stillbirth and neonatal mortality.
Jimenez-Solem E1, Andersen JT, Petersen M, Broedbaek K, Lander AR, Afzal S, Torp-Pedersen C, Poulsen HE.

13)
Arch Dis Child Fetal Neonatal Ed. 2012 Nov;97(6):F472-6. doi: 10.1136/archdischild-2011-214239.
Maternal use of SSRIs, SNRIs and NaSSAs: practical recommendations during pregnancy and lactation.
Sie SD1, Wennink JM, van Driel JJ, te Winkel AG, Boer K, Casteelen G, van Weissenbruch MM.

14) Arch Gen Psychiatry. 2010 Oct;67(10):1012-24. doi: 10.1001/archgenpsychiatry.2010.111.

15) A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction.
Grote NK1, Bridge JA, Gavin AR, Melville JL, Iyengar S, Katon WJ.

16) Kennedy y Einarson (2012), y Grigoriadis et al. (2013).
J Popul Ther Clin Pharmacol. 2012;19(2):e334-48. Epub 2012 Aug 29.
Do findings differ across research design? The case of antidepressant use in pregnancy and malformations.
Einarson TR1, Kennedy D, Einarson A.

17) J Clin Psychiatry. 2013 Apr;74(4):e321-41. doi: 10.4088/JCP.12r07968.
The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis.

REFERENCIAS. APROXIMACIÓN A LOS TRATAMIENTOS PSICOFARMACOLÓGICOS EN EL EMBARAZO.

Grigoriadis S1, VonderPorten EH, Mamisashvili L, Tomlinson G, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, Radford K, Martinovic J, Ross LE.

18) Clomipramine concentration and withdrawal symptoms in 10 neonates
Peter G J ter Horst,1,2 Susanne van der Linde,1 Jan Pieter Smit,3 Jan den
Boon,4 Richard A van Lingen,5 Frank G A Jansman,6 Lolkje T W De Jong-van
den Berg,1 and Bob Wilffert1

19) (Erol S, Ozcan B, Celik IH, et al. Síndrome de abstinencia neonatal debido
a exposición prenatal al citalopram: a propósito de un caso. Arch Argent Pediatr
2017;115(6):e424-e427).

20) Psychopharmacology (Berl). 2011 Sep;217(2):211-9. doi: 10.1007/
s00213-011-2270-z. Epub 2011 Apr 16.

Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI)
antidepressants: effects on neonatal adaptation and psychomotor development.
Casper RC1, Gilles AA, Fleisher BE, Baran J, Enns G, Lazzeroni LC.

21) N Engl J Med. 2006 Feb 9;354(6):579-87.

Selective serotonin-reuptake inhibitors and risk of persistent pulmonary
hypertension of the newborn.

Chambers CD1, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones
KL, Mitchell AA.

22) Am J Psychiatry. 2007 Aug;164(8):1214-20.

Atypical antipsychotic administration during late pregnancy: placental passage
and obstetrical outcomes.

Newport DJ1, Calamaras MR, DeVane CL, Donovan J, Beach AJ, Winn S,
Knight BT, Gibson BB, Viguera AC, Owens MJ, Nemeroff CB, Stowe ZN.

23) Schizophr Bull. 2010 May;36(3):518-44. doi: 10.1093/schbul/sbn107. Epub
2008 Sep 11.

Antipsychotic therapy during early and late pregnancy. A systematic review.
Gentile S1.

24) Can J Psychiatry. 2009 Apr;54(4):242-6.

REFERENCIAS. APROXIMACIÓN A LOS TRATAMIENTOS PSICOFARMACOLÓGICOS EN EL EMBARAZO.

Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study.

[Einarson A1](#), [Choi J](#), [Einarson TR](#), [Koren G](#).

25) [Br J Psychiatry](#). 2008 May;192(5):333-7. doi: 10.1192/bjp.bp.107.041541.

Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study.

[Newham JJ1](#), [Thomas SH](#), [MacRitchie K](#), [McElhatton PR](#), [McAllister-Williams RH](#).

26) [Aust N Z J Psychiatry](#). 2010 Feb;44(2):99-108. doi:

[10.3109/00048670903487217](#).

Management of antipsychotic and mood stabilizer medication in pregnancy: recommendations for antenatal care.

[Galbally M1](#), [Snellen M](#), [Walker S](#), [Permezel M](#).

27) [Depress Anxiety](#). 2010 Jul;27(7):675-86. doi: 10.1002/da.20706.

Neurodevelopmental effects of prenatal exposure to psychotropic medications.

[Gentile S1](#).

28) [Altshuler LL](#), [Cohen L](#), [Szuba M](#) y cols. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. [Am J Psychiatry](#). 1996;153, 5: 592-606

29) [Enato E](#), [Moretti M](#), [Koren G](#). The fetal safety of benzodiazepines: An updated Meta-analysis. [J Obstet Gynaecol Can](#). 2011; 33 (1): 46-48.

30) [Mazaira S](#). Efectos de los psicofármacos en el feto y el recién nacido: Consecuencias del tratamiento de los trastornos psiquiátricos durante el embarazo y lactancia. [Vertex Revista Argentina de Psiquiatría](#). 2005;16:35-42.

31) [Kieviet N](#), [Dolman K](#), [Honig A](#). The use of psychotropic medication during pregnancy: how about the newborn?. [Neuropsychiatric Disease and Treatment](#). 2013; 9:257-1266

32) [Am J Obstet Gynecol](#). 2009 Dec;201(6):579.e1-8. doi: 10.1016/

[j.ajog.2009.06.061](#). Epub 2009 Aug 18.

Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy.

REFERENCIAS. APROXIMACIÓN A LOS TRATAMIENTOS PSICOFARMACOLÓGICOS EN EL EMBARAZO.

Calderon-Margalit R1, Qiu C, Ornoy A, Siscovick DS, Williams MA.

33) Pharmacoepidemiol Drug Saf. 2007 Nov;16(11):1203-10.
Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations.
Wikner BN1, Stiller CO, Bergman U, Asker C, Källén B.

34) Eur J Clin Pharmacol. 2015 Mar;71(3):283-91. doi: 10.1007/s00228-014-1797-4. Epub 2014 Dec 30.
Prenatal exposure to anxiolytics and hypnotics and language competence at 3 years of age.
Odsbu I1, Skurtveit S, Selmer R, Roth C, Hernandez-Diaz S, Handal M

35) Stika et al., " Effects of Drug Administration in Pregnancy on Children's School Behaviour," Pharmaceutisch Weekblad: Scientific Edition 12 (1990): 252-55 (abstract in English).

36) JAMA. 1994 Jan 12;271(2):146-50.
A reevaluation of risk of in utero exposure to lithium.
Cohen LS1, Friedman JM, Jefferson JW, Johnson EM, Weiner ML.

37) Drug treatment for mood disorders in pregnancy
Gentile, Salvatore
Current Opinion in Psychiatry: January 2011 - Volume 24 - Issue 1 - p 34-40
doi: 10.1097/YCO.0b013e3283413451(Gentile, 2011)

38) Isr J Psychiatry Relat Sci. 2008;45(2):95-106.
Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review.
Yacobi S1, Ornoy A.

39) Lancet. 2012 Feb 25;379(9817):721-8. doi: 10.1016/S0140-6736(11)61516-X. Epub 2012 Jan 20.
Lithium toxicity profile: a systematic review and meta-analysis.
McKnight RF1, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR.

40) Pregnancy Outcome Following In Utero Exposure to Lithium: A Prospective, Comparative, Observational Study

REFERENCIAS. APROXIMACIÓN A LOS TRATAMIENTOS PSICOFARMACOLÓGICOS EN EL EMBARAZO.

Orna Diav-Citrin, M.D., Svetlana Shechtman, Ph.D., Esther Tahover, M.D., Victoriya Finkel-Pekarsky, M.Sc.Pharm., Judy Arnon, Ph.D., Debra Kennedy, M.D., Aida Erebara, M.D., Adrienne Einarson, R.N., and Asher Ornoy, M.D.
Published Online: 1 Jul 2014 <https://doi.org/10.1176/appi.ajp.2014.12111402>
Curr Pharm Des. 2006;12(12):1531-41.

41) Am J Psychiatry. 2014 Jul;171(7):712-5. doi: 10.1176/appi.ajp.2014.14030409.
Lithium during pregnancy.
Bergink V, Kushner SA.

42) Am J Psychiatry. 2005 Nov;162(11):2162-70.
Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy.
Newport DJ1, Viguera AC, Beach AJ, Ritchie JC, Cohen LS, Stowe ZN.

43) Br Med J. 1973 Apr 21;2(5859):135-6.
Lithium and pregnancy. I. Report from the Register of Lithium Babies.
Schou M, Goldfield MD, Weinstein MR, Villeneuve A

44) Early Hum Dev. 2012 Jun;88(6):375-8. doi: 10.1016/j.earlhumdev.2011.09.013. Epub 2011 Oct 14.
Fetal, neonatal and developmental outcomes of lithium-exposed pregnancies.
van der Lugt NM1, van de Maat JS, van Kamp IL, Knoppert-van der Klein EA, Hovens JG, Walther FJ.

45) Am J Psychiatry. 2000 Feb;157(2):179-84.
Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance.
Viguera AC1, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RJ.

46) Am J Psychiatry. 2007 Dec;164(12):1817-24; quiz 1923.
Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation.
Viguera AC1, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, Zurick A, Cohen LS.

47) Bipolar Disord. 2004 Feb;6(1):2-13.
Special considerations in treating bipolar disorder in women.
Burt VK1, Rasgon N.

REFERENCIAS. APROXIMACIÓN A LOS TRATAMIENTOS PSICOFARMACOLÓGICOS EN EL EMBARAZO.

48) Am J Psychiatry. 2005 Nov;162(11):2162-70.

Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy.

Newport DJ1, [Viguera AC](#), [Beach AJ](#), [Ritchie JC](#), [Cohen LS](#), [Stowe ZN](#).

49) Expert Opin Drug Saf. 2012 May;11(3):425-37. doi:

10.1517/14740338.2012.670419. Epub 2012 Mar 9.

Lithium in pregnancy: the need to treat, the duty to ensure safety.

Gentile S1.

50) Lancet Neurol. 2012 Sep;11(9):803-13. doi: 10.1016/

S1474-4422(12)70103-5. Epub 2012 Jul 16.

Teratogenic effects of antiepileptic drugs.

Tomson T1, [Battino D](#).

51) Lancet Neurol. 2011 Jul;10(7):609-17. doi: 10.1016/

S1474-4422(11)70107-7. Epub 2011 Jun 5.

Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.

Tomson T1, [Battino D](#), [Bonizzoni E](#), [Craig J](#), [Lindhout D](#), [Sabers A](#), [Perucca E](#), [Vajda F](#); [EURAP study group](#).

52) Am J Psychiatry. 2013 Nov;170(11):1240-7. doi: 10.1176/

appi.ajp.2013.13010006.

Lamotrigine dosing for pregnant patients with bipolar disorder.

Clark CT, [Klein AM](#), [Perel JM](#), [Helsel J](#), [Wisner KL](#). Monitorizar las funciones hepática, renal y tiroidea.